These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 32652311

  • 1. Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications.
    Sisignano M, Steinhilber D, Parnham MJ, Geisslinger G.
    Drug Discov Today; 2020 Sep; 25(9):1744-1753. PubMed ID: 32652311
    [Abstract] [Full Text] [Related]

  • 2. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.
    Karkhanis A, Hong Y, Chan ECY.
    Biochem Pharmacol; 2017 Jul 01; 135():12-21. PubMed ID: 28237650
    [Abstract] [Full Text] [Related]

  • 3. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform.
    Lee B, Wu Z, Sung SH, Lee T, Song KS, Lee MY, Liu KH.
    Food Chem Toxicol; 2014 Aug 01; 70():94-9. PubMed ID: 24788058
    [Abstract] [Full Text] [Related]

  • 4. CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.
    Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC.
    Pharmacol Ther; 2020 Nov 01; 215():107601. PubMed ID: 32534953
    [Abstract] [Full Text] [Related]

  • 5. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.
    Lee E, Wu Z, Shon JC, Liu KH.
    Drug Metab Dispos; 2015 Aug 01; 43(8):1250-3. PubMed ID: 26048912
    [Abstract] [Full Text] [Related]

  • 6. The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2.
    Tian X, Zhou M, Ning J, Deng X, Feng L, Huang H, Yao D, Ma X.
    J Enzyme Inhib Med Chem; 2021 Dec 01; 36(1):737-748. PubMed ID: 33682565
    [Abstract] [Full Text] [Related]

  • 7. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
    Lu J, Liu D, Zhou X, Chen A, Jiang Z, Ye X, Liu M, Wang X.
    Phytomedicine; 2018 Jan 15; 39():137-145. PubMed ID: 29433675
    [Abstract] [Full Text] [Related]

  • 8. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
    Leow JWH, Verma RK, Lim ABH, Fan H, Chan ECY.
    Eur J Pharm Sci; 2021 Sep 01; 164():105889. PubMed ID: 34044117
    [Abstract] [Full Text] [Related]

  • 9. Cardiomyocyte-specific CYP2J2 and its therapeutic implications.
    Valencia R, Bassiouni W, Darwesh AM, Bapuji R, Seubert JM.
    Expert Opin Drug Metab Toxicol; 2022 Sep 01; 18(7-8):423-439. PubMed ID: 35997132
    [Abstract] [Full Text] [Related]

  • 10. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
    Leow JWH, Gu Y, Chan ECY.
    Eur J Pharm Sci; 2023 Aug 01; 187():106475. PubMed ID: 37225005
    [Abstract] [Full Text] [Related]

  • 11. Identification of novel substrates for human cytochrome P450 2J2.
    Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP, Freiwald S, Zientek M, Totah RA.
    Drug Metab Dispos; 2010 Feb 01; 38(2):347-56. PubMed ID: 19923256
    [Abstract] [Full Text] [Related]

  • 12. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
    Phuc NM, Wu Z, O Y, Lee JH, Oh S, Song GY, Liu KH.
    Drug Metab Dispos; 2017 Jul 01; 45(7):765-769. PubMed ID: 28461575
    [Abstract] [Full Text] [Related]

  • 13. Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review.
    Wiley AM, Yang J, Madhani R, Nath A, Totah RA.
    Drug Metab Rev; 2024 Jul 01; 56(2):145-163. PubMed ID: 38478383
    [Abstract] [Full Text] [Related]

  • 14. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.
    Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S.
    Chem Biol Interact; 2019 Jun 01; 306():1-9. PubMed ID: 30965050
    [Abstract] [Full Text] [Related]

  • 15. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
    Evangelista EA, Kaspera R, Mokadam NA, Jones JP, Totah RA.
    Drug Metab Dispos; 2013 Dec 01; 41(12):2087-94. PubMed ID: 24021950
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2.
    Xu MJ, Jiang LF, Wu T, Chu JH, Wei YD, Aa JY, Wang GJ, Hao HP, Ju WZ, Li P.
    Chem Biol Interact; 2018 Jun 01; 289():15-22. PubMed ID: 29689254
    [Abstract] [Full Text] [Related]

  • 17. Asymmetric Binding and Metabolism of Polyunsaturated Fatty Acids (PUFAs) by CYP2J2 Epoxygenase.
    Arnold WR, Baylon JL, Tajkhorshid E, Das A.
    Biochemistry; 2016 Dec 20; 55(50):6969-6980. PubMed ID: 27992998
    [Abstract] [Full Text] [Related]

  • 18. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
    Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CL, Zhou L, Hong Y, Kojodjojo P, Chan EC.
    Biochem Pharmacol; 2016 May 01; 107():67-80. PubMed ID: 26972388
    [Abstract] [Full Text] [Related]

  • 19. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.
    Xu M, Ju W, Hao H, Wang G, Li P.
    Drug Metab Rev; 2013 Aug 01; 45(3):311-52. PubMed ID: 23865864
    [Abstract] [Full Text] [Related]

  • 20. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.
    Xu L, Chen LY.
    Sci Rep; 2020 Dec 17; 10(1):22267. PubMed ID: 33335233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.